So They Say

Notions of NIH Directors: Past,., The fiscal year (FY) 1956 budget [for NIH] became operational on 1 July 1955.... The level of NIH activity at the time... amounted in total to $96.4 million. To some the figure may seem large. But the gross figures had little relevance to the science opportunities it would provide and to the needs of medicine. In view of the need for new knowledge in medicine, the main deficiency preventing progress was the inadequate funding of research.... It was equally

| 5 min read

Register for free to listen to this article
Listen with Speechify
0:00
5:00
Share

The fiscal year (FY) 1956 budget [for NIH] became operational on 1 July 1955.... The level of NIH activity at the time... amounted in total to $96.4 million. To some the figure may seem large. But the gross figures had little relevance to the science opportunities it would provide and to the needs of medicine.

In view of the need for new knowledge in medicine, the main deficiency preventing progress was the inadequate funding of research....

It was equally clear to some of us that success was only possible by breaking out of the confines of the then federal budget for the support of the biomedical sciences. Although resources were then available, this was a temporary situation. A realistic program would have to provide a continuing expansion of the base for scientists’ production and an expansion of physical resources to house the expanding programs. The targets seemed clear.

—James A. ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies